US Patent 11097013 Anti-HER2 antibody-maytansine conjugates and methods of use thereof
Patent 11097013 was granted and assigned to Redwood Bioscience on August, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 3 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+210 characters)
Article
Patent abstract
The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110970130
Date of Patent
August 24, 2021
0Patent Application Number
201809260
Date Filed
September 26, 2018
0Official Website
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110970130
Date of Patent
August 24, 2021
0Patent Application Number
201809260
Date Filed
September 26, 2018
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 5 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11097013 Anti-HER2 antibody-maytansine conjugates and methods of use thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11097013
Date of patent
August 24, 2021
Patent application number
20180926
Date Filed
September 26, 2018
Find more entities like US Patent 11097013 Anti-HER2 antibody-maytansine conjugates and methods of use thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
